BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1365@pharmaconomics
DTSTAMP:20260707T015757Z
DTSTART;VALUE=DATE:20251222
DTEND;VALUE=DATE:20251223
SUMMARY:TLX Phase 3 — Illuccix
DESCRIPTION:Phase 3 trial results for Illuccix in prostate cancer imaging are due Dec 22\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/2007191/000200719126000004/chinapr.htm\n\nTrack it: https://pharmaconomics.com/e/1365
URL:https://pharmaconomics.com/e/1365
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:TLX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR